The FDA says Torrent finished product batches were out of spec 340 times in two years, but the company often approved them after retesting.

Takeda sells meds to Novartis and J&J; Daiichi's AZ-shared HER2 antibody-drug conjugate hits key trial goal; Sun scouts for Chinese partner.

AZ warns of slower China growth; BeiGene chief ranks among highest-paid biopharma CEOs; Kangmei faces delisting over huge accounting "error."

Keytruda grew sales by 60% at constant currencies, boosting its share in Merck's portfolio. Could China and a few new indications step on the gas?

Lilly sells legacy antibiotics in China; Daiichi picks a bispecific antibody in Zymeworks deal; Torrent recalls more than 1 million losartan bottles.

China sales and older meds helped boost Bayer's pharma results, but those numbers couldn't eclipse concerns about mushrooming Monsanto litigation.

Sun Pharma has been issued a Form 483, Catalent is investing $14 million at a facility in Germany and more manufacturing news of note.

Amid China's tighter grip on antibiotics use, Lilly sold Chinese rights to two legacy antibiotics and a manufacturing facility to China's Eddingpharm.